Pharmacokinetics of carbetocin, a long-acting oxytocin analogue, in nonpregnant women

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Standard

Pharmacokinetics of carbetocin, a long-acting oxytocin analogue, in nonpregnant women. / Sweeney, G.; Holbrook, A. M.; Levine, M.; Yip, M.; Alfredsson, K.; Cappi, S.; Ohlin, M.; Schulz, P.; Wassenaar, W.

I: Current Therapeutic Research - Clinical and Experimental, Vol. 47, Nr. 3, 1990, s. 528-540.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Harvard

Sweeney, G, Holbrook, AM, Levine, M, Yip, M, Alfredsson, K, Cappi, S, Ohlin, M, Schulz, P & Wassenaar, W 1990, 'Pharmacokinetics of carbetocin, a long-acting oxytocin analogue, in nonpregnant women', Current Therapeutic Research - Clinical and Experimental, vol. 47, nr. 3, s. 528-540.

APA

Sweeney, G., Holbrook, A. M., Levine, M., Yip, M., Alfredsson, K., Cappi, S., Ohlin, M., Schulz, P., & Wassenaar, W. (1990). Pharmacokinetics of carbetocin, a long-acting oxytocin analogue, in nonpregnant women. Current Therapeutic Research - Clinical and Experimental, 47(3), 528-540.

CBE

Sweeney G, Holbrook AM, Levine M, Yip M, Alfredsson K, Cappi S, Ohlin M, Schulz P, Wassenaar W. 1990. Pharmacokinetics of carbetocin, a long-acting oxytocin analogue, in nonpregnant women. Current Therapeutic Research - Clinical and Experimental. 47(3):528-540.

MLA

Vancouver

Author

Sweeney, G. ; Holbrook, A. M. ; Levine, M. ; Yip, M. ; Alfredsson, K. ; Cappi, S. ; Ohlin, M. ; Schulz, P. ; Wassenaar, W. / Pharmacokinetics of carbetocin, a long-acting oxytocin analogue, in nonpregnant women. I: Current Therapeutic Research - Clinical and Experimental. 1990 ; Vol. 47, Nr. 3. s. 528-540.

RIS

TY - JOUR

T1 - Pharmacokinetics of carbetocin, a long-acting oxytocin analogue, in nonpregnant women

AU - Sweeney, G.

AU - Holbrook, A. M.

AU - Levine, M.

AU - Yip, M.

AU - Alfredsson, K.

AU - Cappi, S.

AU - Ohlin, M.

AU - Schulz, P.

AU - Wassenaar, W.

PY - 1990

Y1 - 1990

N2 - The safety and pharmacokinetics of carbetocin, a long-acting oxytocin analogue, were studied in 25 healthy nonpregnant women. The distribution and elimination half-lives of a 0.4-mg intravenous dose were found to be 5.5 ± 1.6 minutes and 41 ± 11.9 minutes, respectively. Similarly, the half-lives of a 0.8-mg intravenous dose were found to be 6.1 ± 1.2 minutes and 42.7 ± 10.6 minutes. Approximately 0.7% of the carbetocin dose was eliminated in the unchanged form by the kidney, indicating that carbetocin, like oxytocin, is eliminated primarily by nonrenal routes. Intramuscularly (IM) administered carbetocin was found to enter the circulation rapidly, with a time to peak concentration of less than 30 minutes. The absolute bioavailability of carbetocin injected IM was approximately 80%. Doses of carbetocin of 0.05 to 0.8 mg produced very few side effects. Included were transient facial flushing and mild transient tachycardia accompanied by a decrease in diastolic blood pressure. The increase in heart rate was significant (P <0.05) after the administration of 0.4- and 0.8-mg IM doses, while the decrease in diastolic blood pressure was significant after the 0.8-mg IM dose only. No clinically significant changes between predrug and postdrug chemistry values of hematology parameters were noted.

AB - The safety and pharmacokinetics of carbetocin, a long-acting oxytocin analogue, were studied in 25 healthy nonpregnant women. The distribution and elimination half-lives of a 0.4-mg intravenous dose were found to be 5.5 ± 1.6 minutes and 41 ± 11.9 minutes, respectively. Similarly, the half-lives of a 0.8-mg intravenous dose were found to be 6.1 ± 1.2 minutes and 42.7 ± 10.6 minutes. Approximately 0.7% of the carbetocin dose was eliminated in the unchanged form by the kidney, indicating that carbetocin, like oxytocin, is eliminated primarily by nonrenal routes. Intramuscularly (IM) administered carbetocin was found to enter the circulation rapidly, with a time to peak concentration of less than 30 minutes. The absolute bioavailability of carbetocin injected IM was approximately 80%. Doses of carbetocin of 0.05 to 0.8 mg produced very few side effects. Included were transient facial flushing and mild transient tachycardia accompanied by a decrease in diastolic blood pressure. The increase in heart rate was significant (P <0.05) after the administration of 0.4- and 0.8-mg IM doses, while the decrease in diastolic blood pressure was significant after the 0.8-mg IM dose only. No clinically significant changes between predrug and postdrug chemistry values of hematology parameters were noted.

UR - http://www.scopus.com/inward/record.url?scp=0025285197&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0025285197

VL - 47

SP - 528

EP - 540

JO - Current Therapeutic Research - Clinical and Experimental

JF - Current Therapeutic Research - Clinical and Experimental

SN - 0011-393X

IS - 3

ER -